{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:18:34Z","timestamp":1779297514510,"version":"3.51.4"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"DOI":"10.1007\/s13577-025-01179-x","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T08:15:54Z","timestamp":1738397754000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of RhoA-ROCK signaling in benign prostatic hyperplasia: a review"],"prefix":"10.1007","volume":"38","author":[{"given":"Shidong","family":"Shan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4999-2886","authenticated-orcid":false,"given":"Min","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"issue":"Suppl 3","key":"1179_CR1","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.3949\/ccjm.74.Suppl_3.S15","volume":"74","author":"A Levy","year":"2007","unstructured":"Levy A, Samraj GP. Benign prostatic hyperplasia: when to \u2018watch and wait\u2019, when and how to treat. Cleve Clin J Med. 2007;74(Suppl 3):S15\u201320.","journal-title":"Cleve Clin J Med"},{"key":"1179_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/pros.2990150506","volume":"2","author":"JT Isaacs","year":"1989","unstructured":"Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl. 1989;2:33\u201350.","journal-title":"Prostate Suppl"},{"key":"1179_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/pros.2990050510","volume":"5","author":"JT Isaacs","year":"1984","unstructured":"Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate. 1984;5:545\u201357.","journal-title":"Prostate"},{"key":"1179_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S0090-4295(94)80197-5","volume":"44","author":"AW Partin","year":"1994","unstructured":"Partin AW, Page WF, Lee BR, Sanda MG, Miller RN, Walsh PC. Concordance rates for benign prostatic disease among twins suggest hereditary influence. Urology. 1994;44:646\u201350.","journal-title":"Urology"},{"key":"1179_CR5","doi-asserted-by":"crossref","unstructured":"McVary K. (2006) Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int. 97 Suppl 2, 23\u201328, 44\u201345.","DOI":"10.1111\/j.1464-410X.2006.06102.x"},{"key":"1179_CR6","first-page":"96","volume":"66","author":"G Theyer","year":"1992","unstructured":"Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, Zechner O, Steiner GE. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Investig. 1992;66:96\u2013107.","journal-title":"Lab Investig"},{"key":"1179_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bju.15229","volume":"127","author":"CM Devlin","year":"2021","unstructured":"Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia\u2014what do we know? BJU Int. 2021;127:389\u201399.","journal-title":"BJU Int"},{"key":"1179_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11934-019-0917-1","volume":"20","author":"GL Lloyd","year":"2019","unstructured":"Lloyd GL, Marks JM, Ricke WA. Benign prostatic hyperplasia and lower urinary tract symptoms: what is the role and significance of inflammation? Curr Urol Rep. 2019;20:54.","journal-title":"Curr Urol Rep"},{"key":"1179_CR9","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bju.15286","volume":"127","author":"BM Launer","year":"2021","unstructured":"Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising worldwide impact of benign prostatic hyperplasia. BJU Int. 2021;127:722\u20138.","journal-title":"BJU Int"},{"key":"1179_CR10","first-page":"843","volume":"117","author":"A Miernik","year":"2020","unstructured":"Miernik A, Gratzke C. Current treatment for benign prostatic hyperplasia. Deutsches Arzteblatt Int. 2020;117:843\u201354.","journal-title":"Deutsches Arzteblatt Int"},{"key":"1179_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0092-8674(85)90058-3","volume":"41","author":"P Madaule","year":"1985","unstructured":"Madaule P, Axel R. A novel ras-related gene family. Cell. 1985;41:31\u201340.","journal-title":"Cell"},{"key":"1179_CR12","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1242\/jcs.03428","volume":"120","author":"RJ Buchsbaum","year":"2007","unstructured":"Buchsbaum RJ. Rho activation at a glance. J Cell Sci. 2007;120:1149\u201352.","journal-title":"J Cell Sci"},{"key":"1179_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2023.107942","volume":"215","author":"H Jiang","year":"2023","unstructured":"Jiang H, Zu S, Lu Y, Sun Z, Adeerjiang A, Guo Q, Zhang H, Dong C, Wu Q, Ding H, Du D, Wang M, Liu C, Tang Y, Liang Z, Luo C. A RhoA structure with switch II flipped outward revealed the conformational dynamics of switch II region. J Struct Biol. 2023;215: 107942.","journal-title":"J Struct Biol"},{"key":"1179_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.cellbio.21.020604.150721","volume":"21","author":"AB Jaffe","year":"2005","unstructured":"Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005;21:247\u201369.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"1179_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1126\/science.279.5350.509","volume":"279","author":"A Hall","year":"1998","unstructured":"Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279:509\u201314.","journal-title":"Science"},{"key":"1179_CR16","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41563-021-01108-x","volume":"21","author":"S Seetharaman","year":"2022","unstructured":"Seetharaman S, Vianay B, Roca V, Farrugia AJ, De Pascalis C, Boeda B, Dingli F, Loew D, Vassilopoulos S, Bershadsky A, Thery M, Etienne-Manneville S. Microtubules tune mechanosensitive cell responses. Nat Mater. 2022;21:366\u201377.","journal-title":"Nat Mater"},{"key":"1179_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1042\/EBC20190015","volume":"63","author":"M Schaks","year":"2019","unstructured":"Schaks M, Giannone G, Rottner K. Actin dynamics in cell migration. Essays Biochem. 2019;63:483\u201395.","journal-title":"Essays Biochem"},{"key":"1179_CR18","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1128\/MCB.16.10.5313","volume":"16","author":"T Leung","year":"1996","unstructured":"Leung T, Chen XQ, Manser E, Lim L. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol. 1996;16:5313\u201327.","journal-title":"Mol Cell Biol"},{"key":"1179_CR19","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1002\/j.1460-2075.1996.tb00574.x","volume":"15","author":"T Matsui","year":"1996","unstructured":"Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Rho-associated kinase, a novel serine\/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 1996;15:2208\u201316.","journal-title":"EMBO J"},{"key":"1179_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.imlet.2019.12.012","volume":"219","author":"R Shahbazi","year":"2020","unstructured":"Shahbazi R, Baradaran B, Khordadmehr M, Safaei S, Baghbanzadeh A, Jigari F, Ezzati H. Targeting ROCK signaling in health, malignant and non-malignant diseases. Immunol Lett. 2020;219:15\u201326.","journal-title":"Immunol Lett."},{"key":"1179_CR21","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1080\/07391102.2018.1491420","volume":"37","author":"SB Bayel","year":"2019","unstructured":"Bayel SB, Tatar G, Taskin TT. Determination of potential selective inhibitors for ROCKI and ROCKII isoforms with molecular modeling techniques: structure based docking, ADMET and molecular dynamics simulation. J Biomol Struct Dyn. 2019;37:2457\u201363.","journal-title":"J Biomol Struct Dyn"},{"key":"1179_CR22","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.drudis.2019.11.017","volume":"25","author":"P Sharma","year":"2020","unstructured":"Sharma P, Roy K. ROCK-2-selective targeting and its therapeutic outcomes. Drug Dis Today. 2020;25:446\u201355.","journal-title":"Drug Dis Today"},{"key":"1179_CR23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1161\/01.RES.0000201960.04223.3c","volume":"98","author":"G Loirand","year":"2006","unstructured":"Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res. 2006;98:322\u201334.","journal-title":"Circ Res"},{"key":"1179_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000502914","volume":"105","author":"W Lu","year":"2020","unstructured":"Lu W, Wen J, Chen Z. Distinct roles of ROCK1 and ROCK2 on the cerebral ischemia injury and subsequently neurodegenerative changes. Pharmacol. 2020;105:3\u20138.","journal-title":"Pharmacol"},{"key":"1179_CR25","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1002\/1873-3468.13087","volume":"592","author":"S Narumiya","year":"2018","unstructured":"Narumiya S, Thumkeo D. Rho signaling research: history, current status and future directions. Febs Lett. 2018;592:1763\u201376.","journal-title":"Febs Lett"},{"key":"1179_CR26","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1743-6109.2010.02084.x","volume":"8","author":"S Gur","year":"2011","unstructured":"Gur S, Kadowitz PJ, Hellstrom WJ. RhoA\/Rho-kinase as a therapeutic target for the male urogenital tract. J Sex Med. 2011;8:675\u201387.","journal-title":"J Sex Med"},{"key":"1179_CR27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s00540-006-0487-5","volume":"21","author":"T Akata","year":"2007","unstructured":"Akata T. Cellular and molecular mechanisms regulating vascular tone. Part 1: basic mechanisms controlling cytosolic Ca2+ concentration and the Ca2+-dependent regulation of vascular tone. J Anesth. 2007;21:220\u201331.","journal-title":"J Anesth"},{"key":"1179_CR28","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/372231a0","volume":"372","author":"AP Somlyo","year":"1994","unstructured":"Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature. 1994;372:231\u20136.","journal-title":"Nature"},{"key":"1179_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1126\/science.273.5272.245","volume":"273","author":"K Kimura","year":"1996","unstructured":"Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science. 1996;273:245\u20138.","journal-title":"Science"},{"key":"1179_CR30","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S0014-5793(97)00657-1","volume":"410","author":"M Eto","year":"1997","unstructured":"Eto M, Senba S, Morita F, Yazawa M. Molecular cloning of a novel phosphorylation-dependent inhibitory protein of protein phosphatase-1 (CPI17) in smooth muscle: its specific localization in smooth muscle. Febs Lett. 1997;410:356\u201360.","journal-title":"Febs Lett"},{"key":"1179_CR31","first-page":"40","volume":"45","author":"M Ito","year":"2022","unstructured":"Ito M, Okamoto R, Ito H, Zhe Y, Dohi K. Regulation of myosin light-chain phosphorylation and its roles in cardiovascular physiology and pathophysiology. Hyp Res. 2022;45:40\u201352.","journal-title":"Hyp Res"},{"key":"1179_CR32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/11056","volume":"1","author":"N Watanabe","year":"1999","unstructured":"Watanabe N, Kato T, Fujita A, Ishizaki T, Narumiya S. Cooperation between mDia1 and ROCK in Rho-induced actin reorganization. Nat Cell Biol. 1999;1:136\u201343.","journal-title":"Nat Cell Biol"},{"key":"1179_CR33","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.3390\/ijms22063279","volume":"22","author":"JC Lauer","year":"2021","unstructured":"Lauer JC, Selig M, Hart ML, Kurz B, Rolauffs B. Articular chondrocyte phenotype regulation through the cytoskeleton and the signaling processes that originate from or converge on the cytoskeleton: towards a novel understanding of the intersection between actin dynamics and chondrogenic function. Int J Mol Sci. 2021;22:3279.","journal-title":"Int J Mol Sci"},{"key":"1179_CR34","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1097\/01.ju.0000085024.47406.6c","volume":"170","author":"RW Rees","year":"2003","unstructured":"Rees RW, Foxwell NA, Ralph DJ, Kell PD, Moncada S, Cellek S. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol. 2003;170:2517\u201322.","journal-title":"J Urol"},{"key":"1179_CR35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/nau.22990","volume":"36","author":"FB Calmasini","year":"2017","unstructured":"Calmasini FB, Silva FH, Alexandre EC, Rodrigues RL, Barbosa AP, Ferrucci DL, Carvalho HF, Anhe GF, Pupo AS, Antunes E. Implication of Rho-kinase and soluble guanylyl cyclase enzymes in prostate smooth muscle dysfunction in middle-aged rats. Neurourol Urodyn. 2017;36:589\u201396.","journal-title":"Neurourol Urodyn"},{"key":"1179_CR36","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.juro.2012.08.220","volume":"189","author":"M Lam","year":"2013","unstructured":"Lam M, Kerr KP, Exintaris B. Involvement of Rho-kinase signaling pathways in nerve evoked and spontaneous contractions of the Guinea pig prostate. J Urol. 2013;189:1147\u201354.","journal-title":"J Urol"},{"key":"1179_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ejphar.2013.09.012","volume":"721","author":"CW White","year":"2013","unstructured":"White CW, Short JL, Ventura S. Rho kinase activation mediates adrenergic and cholinergic smooth muscle contractile responses in the mouse prostate gland. Eur J Pharmacol. 2013;721:313\u201321.","journal-title":"Eur J Pharmacol"},{"key":"1179_CR38","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/nau.20365","volume":"26","author":"R Takahashi","year":"2007","unstructured":"Takahashi R, Nishimura J, Seki N, Yunoki T, Tomoda T, Kanaide H, Naito S. RhoA\/Rho kinase-mediated Ca2+ sensitization in the contraction of human prostate. Neurourol Urodyn. 2007;26:547\u201351.","journal-title":"Neurourol Urodyn"},{"key":"1179_CR39","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ejphar.2010.10.052","volume":"650","author":"F Strittmatter","year":"2011","unstructured":"Strittmatter F, Gratzke C, Weinhold P, Steib CJ, Hartmann AC, Schlenker B, Andersson KE, Hedlund P, Stief CG, Hennenberg M. Thromboxane A2 induces contraction of human prostate smooth muscle by Rho kinase- and calmodulin-dependent mechanisms. Eur J Pharmacol. 2011;650:650\u20135.","journal-title":"Eur J Pharmacol"},{"key":"1179_CR40","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejphar.2015.03.057","volume":"758","author":"FB Calmasini","year":"2015","unstructured":"Calmasini FB, Leiria LO, Alves JM, Bau FR, Alexandre EC, Silva FH, Monica FZ, Antunes E. Increased Rho-kinase-mediated prostate contractions associated with impairment of beta-adrenergic-cAMP-signaling pathway by chronic nitric oxide deficiency. Eur J Pharmacol. 2015;758:24\u201330.","journal-title":"Eur J Pharmacol"},{"key":"1179_CR41","doi-asserted-by":"publisher","first-page":"12231","DOI":"10.1074\/jbc.RA119.007958","volume":"294","author":"Q Yu","year":"2019","unstructured":"Yu Q, Gratzke C, Wang R, Li B, Kuppermann P, Herlemann A, Tamalunas A, Wang Y, Rutz B, Ciotkowska A, Wang X, Strittmatter F, Waidelich R, Stief CG, Hennenberg M. A NAV2729-sensitive mechanism promotes adrenergic smooth muscle contraction and growth of stromal cells in the human prostate. J Biol Chem. 2019;294:12231\u201349.","journal-title":"J Biol Chem"},{"key":"1179_CR42","doi-asserted-by":"publisher","first-page":"F47","DOI":"10.1152\/ajprenal.00125.2017","volume":"314","author":"A Herlemann","year":"2018","unstructured":"Herlemann A, Keller P, Schott M, Tamalunas A, Ciotkowska A, Rutz B, Wang Y, Yu Q, Waidelich R, Strittmatter F, Stief CG, Gratzke C, Hennenberg M. Inhibition of smooth muscle contraction and ARF6 activity by the inhibitor for cytohesin GEFs, secinH3, in the human prostate. Am J Physiol Renal Physiol. 2018;314:F47\u201357.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1179_CR43","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/BF00297193","volume":"22","author":"J Nordling","year":"1994","unstructured":"Nordling J. Definition of prostatic urethral obstruction. Urol Res. 1994;22:267\u201371.","journal-title":"Urol Res"},{"key":"1179_CR44","doi-asserted-by":"publisher","first-page":"C542","DOI":"10.1152\/ajpcell.00033.2014","volume":"307","author":"E Boopathi","year":"2014","unstructured":"Boopathi E, Gomes C, Zderic SA, Malkowicz B, Chakrabarti R, Patel DP, Wein AJ, Chacko S. Mechanical stretch upregulates proteins involved in Ca2+ sensitization in urinary bladder smooth muscle hypertrophy. Am J Physiol Cell Physiol. 2014;307:C542\u201353.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1179_CR45","doi-asserted-by":"publisher","first-page":"F990","DOI":"10.1152\/ajprenal.00378.2002","volume":"285","author":"W Bing","year":"2003","unstructured":"Bing W, Chang S, Hypolite JA, DiSanto ME, Zderic SA, Rolf L, Wein AJ, Chacko S. Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am J Physiol Renal Physiol. 2003;285:F990\u20137.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1179_CR46","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/S0022-5347(06)00281-3","volume":"175","author":"O Demir","year":"2006","unstructured":"Demir O, Murat N, Aslan G, Gidener S, Esen AA. Effect of doxazosin with and without rho-kinase inhibitor on human corpus cavernosum smooth muscle in the presence of bladder outlet obstruction. J Urol. 2006;175:2345\u20139.","journal-title":"J Urol"},{"key":"1179_CR47","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/nau.20607","volume":"27","author":"WY Lin","year":"2008","unstructured":"Lin WY, Mannikarottu A, Chichester P, Neuman P, Johnson A, Perez-Martinez FC, Levin RM. The effect of chronic partial bladder outlet obstruction on corpus cavernosum smooth muscle and Rho-kinase in rabbits. Neurourol Urodyn. 2008;27:826\u201331.","journal-title":"Neurourol Urodyn"},{"key":"1179_CR48","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/nau.20625","volume":"28","author":"N Takahashi","year":"2009","unstructured":"Takahashi N, Shiomi H, Kushida N, Liu F, Ishibashi K, Yanagida T, Shishido K, Aikawa K, Yamaguchi O. Obstruction alters muscarinic receptor-coupled RhoA\/Rho-kinase pathway in the urinary bladder of the rat. Neurourol Urodyn. 2009;28:257\u201362.","journal-title":"Neurourol Urodyn"},{"key":"1179_CR49","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0022-5347(17)37546-8","volume":"147","author":"E Shapiro","year":"1992","unstructured":"Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol. 1992;147:1293\u20137.","journal-title":"J Urol"},{"key":"1179_CR50","first-page":"83","volume":"26","author":"JC Zhang","year":"2020","unstructured":"Zhang JC, Zhao F, Duan Y. Prostatic fibrosis: progress in studies. Zhonghua Nan Ke Xue. 2020;26:83\u20137.","journal-title":"Zhonghua Nan Ke Xue"},{"key":"1179_CR51","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0168-8278(01)00169-6","volume":"35","author":"T Murata","year":"2001","unstructured":"Murata T, Arii S, Nakamura T, Mori A, Kaido T, Furuyama H, Furumoto K, Nakao T, Isobe N, Imamura M. Inhibitory effect of Y-27632, a ROCK inhibitor, on progression of rat liver fibrosis in association with inactivation of hepatic stellate cells. J Hepatol. 2001;35:474\u201381.","journal-title":"J Hepatol"},{"key":"1179_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154140","volume":"104","author":"Q Cai","year":"2020","unstructured":"Cai Q, Chen F, Xu F, Wang K, Zhang K, Li G, Chen J, Deng H, He Q. Epigenetic silencing of microRNA-125b-5p promotes liver fibrosis in nonalcoholic fatty liver disease via integrin alpha8-mediated activation of RhoA signaling pathway. Metabol-Clin Exp. 2020;104: 154140.","journal-title":"Metabol-Clin Exp"},{"key":"1179_CR53","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1165\/rcmb.2017-0075OC","volume":"58","author":"RS Knipe","year":"2018","unstructured":"Knipe RS, Probst CK, Lagares D, Franklin A, Spinney JJ, Brazee PL, Grasberger P, Zhang L, Black KE, Sakai N, Shea BS, Liao JK, Medoff BD, Tager AM. The Rho kinase isoforms ROCK1 and ROCK2 each contribute to the development of experimental pulmonary fibrosis. Am J Respir Cell Mol Biol. 2018;58:471\u201381.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1179_CR54","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/cvr\/cvp135","volume":"83","author":"SB Haudek","year":"2009","unstructured":"Haudek SB, Gupta D, Dewald O, Schwartz RJ, Wei L, Trial J, Entman ML. Rho kinase-1 mediates cardiac fibrosis by regulating fibroblast precursor cell differentiation. Cardiovasc Res. 2009;83:511\u20138.","journal-title":"Cardiovasc Res"},{"key":"1179_CR55","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1046\/j.1523-1755.2002.00328.x","volume":"61","author":"K Nagatoya","year":"2002","unstructured":"Nagatoya K, Moriyama T, Kawada N, Takeji M, Oseto S, Murozono T, Ando A, Imai E, Hori M. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kid Int. 2002;61:1684\u201395.","journal-title":"Kid Int"},{"key":"1179_CR56","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/cbf.3382","volume":"37","author":"DG Ibrahim","year":"2019","unstructured":"Ibrahim DG, Ko JA, Iwata W, Okumichi H, Kiuchi Y. An in vitro study of scarring formation mediated by human Tenon fibroblasts: effect of Y-27632, a Rho kinase inhibitor. Cell Biochem Funct. 2019;37:113\u201324.","journal-title":"Cell Biochem Funct"},{"key":"1179_CR57","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1021\/acs.jmedchem.2c01753","volume":"66","author":"Y Xie","year":"2023","unstructured":"Xie Y, Yue L, Shi Y, Su X, Gan C, Liu H, Xue T, Ye T. Application and study of ROCK inhibitors in pulmonary fibrosis: recent developments and future perspectives. J Med Chem. 2023;66:4342\u201360.","journal-title":"J Med Chem"},{"key":"1179_CR58","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-022-00925-z","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Wang L, Wang S, Cheng H, Xu L, Pei G, Wang Y, Fu C, Jiang Y, He C, Wei Q. Signaling pathways and targeted therapy for myocardial infarction. Signal Transduct Target Ther. 2022;7:78.","journal-title":"Signal Transduct Target Ther"},{"key":"1179_CR59","doi-asserted-by":"publisher","first-page":"6833867","DOI":"10.1155\/2022\/6833867","volume":"2022","author":"D Lin","year":"2022","unstructured":"Lin D, Zhang M, Luo C, Wei P, Cui K, Chen Z. Targeting ferroptosis attenuates inflammation, fibrosis, and mast cell activation in chronic prostatitis. J Immunol Res. 2022;2022:6833867.","journal-title":"J Immunol Res"},{"key":"1179_CR60","doi-asserted-by":"publisher","first-page":"8877540","DOI":"10.1155\/2021\/8877540","volume":"2021","author":"M Zhang","year":"2021","unstructured":"Zhang M, Luo C, Lin D, Cui K, Chen Z, Liu J. Human tissue Kallikrein 1 is downregulated in elderly human prostates and possesses potential in vitro antioxidative and antifibrotic effects in rodent prostates. Oxid Med Cell Longev. 2021;2021:8877540.","journal-title":"Oxid Med Cell Longev"},{"key":"1179_CR61","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s10020-023-00734-2","volume":"29","author":"S Shan","year":"2023","unstructured":"Shan S, Su M, Li Y, Wang Z, Liu D, Zhou Y, Fu X, Yang S, Zhang J, Qiu J, Liu H, Zeng G, Chen P, Wang X, DiSanto ME, Guo Y, Zhang X. Mechanism of RhoA regulating benign prostatic hyperplasia: RhoA-ROCK-beta-catenin signaling axis and static & dynamic dual roles. Mol Med. 2023;29:139.","journal-title":"Mol Med"},{"key":"1179_CR62","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s43556-024-00216-9","volume":"5","author":"S Shan","year":"2024","unstructured":"Shan S, Su M, Wang H, Guo F, Li Y, Zhou Y, Liu H, Du L, Zhang J, Qiu J, DiSanto ME, Guo Y, Zhang X. Y-27632 targeting ROCK1&2 modulates cell growth, fibrosis and epithelial-mesenchymal transition in hyperplastic prostate by inhibiting beta-catenin pathway. Mol Biomed. 2024;5:52.","journal-title":"Mol Biomed"},{"key":"1179_CR63","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.ijrobp.2017.06.2449","volume":"99","author":"J Mahmood","year":"2017","unstructured":"Mahmood J, Connors CQ, Alexander AA, Pavlovic R, Samanta S, Soman S, Matsui H, Sopko NA, Bivalacqua TJ, Weinreich D, Ho CY, Eley J, Sawant A, Jackson IL, Vujaskovic Z. Cavernous nerve injury by radiation therapy may potentiate erectile dysfunction in rats. Int J Radiat Oncol Biol Phys. 2017;99:680\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1179_CR64","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.radonc.2020.06.021","volume":"150","author":"J Mahmood","year":"2020","unstructured":"Mahmood J, Pandita R, Zhang A, Kamlapurkar S, Saeed A, Chen M, Staats PN, Shukla HD, Anvari A, Sawant A, Vujaskovic Z. RhoA\/ROCK pathway inhibitor ameliorates erectile dysfunction induced by radiation therapy in rats. Radiother Oncol. 2020;150:174\u201380.","journal-title":"Radiother Oncol"},{"key":"1179_CR65","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10137","volume":"474","author":"S Dupont","year":"2011","unstructured":"Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, Elvassore N, Piccolo S. Role of YAP\/TAZ in mechanotransduction. Nature. 2011;474:179\u201383.","journal-title":"Nature"},{"key":"1179_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2023.102208","volume":"83","author":"KM Young","year":"2023","unstructured":"Young KM, Reinhart-King CA. Cellular mechanosignaling for sensing and transducing matrix rigidity. Curr Opin Cell Biol. 2023;83: 102208.","journal-title":"Curr Opin Cell Biol"},{"key":"1179_CR67","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.7150\/thno.35665","volume":"9","author":"S Li","year":"2019","unstructured":"Li S, Li C, Zhang Y, He X, Chen X, Zeng X, Liu F, Chen Y, Chen J. Targeting mechanics-induced fibroblast activation through CD44-RhoA-YAP pathway ameliorates crystalline silica-induced silicosis. Theranostics. 2019;9:4993\u20135008.","journal-title":"Theranostics"},{"key":"1179_CR68","doi-asserted-by":"publisher","first-page":"e2304274","DOI":"10.1002\/advs.202304274","volume":"11","author":"D Lin","year":"2024","unstructured":"Lin D, Luo C, Wei P, Zhang A, Zhang M, Wu X, Deng B, Li Z, Cui K, Chen Z. YAP1 recognizes inflammatory and mechanical cues to exacerbate benign prostatic hyperplasia via promoting cell survival and fibrosis. Adv Sci. 2024;11:e2304274.","journal-title":"Adv Sci"},{"key":"1179_CR69","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/pros.20896","volume":"69","author":"G Penna","year":"2009","unstructured":"Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E, Chavalmane A, Morelli A, Sarchielli E, Vannelli GB, Gacci M, Colli E, Maggi M, Adorini L. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA\/Rho kinase and NF-kappaB pathways. Prostate. 2009;69:480\u201393.","journal-title":"Prostate"},{"key":"1179_CR70","first-page":"391","volume":"18","author":"G Zhang","year":"2018","unstructured":"Zhang G, Zhu F, Han G, Li Z, Yu Q, Li Z, Li J. Silencing of URG11 expression inhibits the proliferation and epithelial-mesenchymal transition in benign prostatic hyperplasia cells via the RhoA\/ROCK1 pathway. Mol Med Rep. 2018;18:391\u20138.","journal-title":"Mol Med Rep"},{"key":"1179_CR71","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.lfs.2017.10.016","volume":"191","author":"BE Tepedelen","year":"2017","unstructured":"Tepedelen BE, Soya E, Korkmaz M. Epigallocatechin-3-gallate reduces the proliferation of benign prostatic hyperplasia cells via regulation of focal adhesions. Life Sci. 2017;191:74\u201381.","journal-title":"Life Sci"},{"key":"1179_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121928","volume":"329","author":"R Wang","year":"2023","unstructured":"Wang R, Huang R, Liu Y, Tamalunas A, Stief CG, Hennenberg M. Silencing of CDC42 inhibits contraction and growth-related functions in prostate stromal cells, which is mimicked by ML141. Life Sci. 2023;329: 121928.","journal-title":"Life Sci"},{"key":"1179_CR73","doi-asserted-by":"publisher","first-page":"10693","DOI":"10.1111\/jcmm.15689","volume":"24","author":"ZX Huang","year":"2020","unstructured":"Huang ZX, Mao XM, Wu RF, Huang SM, Ding XY, Chen QH, Chen QX. RhoA\/ROCK pathway mediates the effect of oestrogen on regulating epithelial-mesenchymal transition and proliferation in endometriosis. J Cell Mol Med. 2020;24:10693\u2013704.","journal-title":"J Cell Mol Med"},{"key":"1179_CR74","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.phrs.2018.05.011","volume":"133","author":"L Tang","year":"2018","unstructured":"Tang L, Dai F, Liu Y, Yu X, Huang C, Wang Y, Yao W. RhoA\/ROCK signaling regulates smooth muscle phenotypic modulation and vascular remodeling via the JNK pathway and vimentin cytoskeleton. Pharmacol Res. 2018;133:201\u201312.","journal-title":"Pharmacol Res"},{"key":"1179_CR75","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3389\/fncel.2018.00437","volume":"12","author":"D Tan","year":"2018","unstructured":"Tan D, Wen J, Li L, Wang X, Qian C, Pan M, Lai M, Deng J, Hu X, Zhang H, Guo J. Inhibition of RhoA-subfamily GTPases suppresses Schwann cell proliferation through regulating AKT pathway rather than ROCK pathway. Front Cell Neurosci. 2018;12:437.","journal-title":"Front Cell Neurosci"},{"key":"1179_CR76","doi-asserted-by":"publisher","first-page":"R570","DOI":"10.1016\/j.cub.2018.03.045","volume":"28","author":"A Basant","year":"2018","unstructured":"Basant A, Glotzer M. Spatiotemporal Regulation of RhoA during cytokinesis. Curr Biol. 2018;28:R570\u201380.","journal-title":"Curr Biol."},{"key":"1179_CR77","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1083\/jcb.201603025","volume":"213","author":"E Wagner","year":"2016","unstructured":"Wagner E, Glotzer M. Local RhoA activation induces cytokinetic furrows independent of spindle position and cell cycle stage. J Cell Biol. 2016;213:641\u20139.","journal-title":"J Cell Biol."},{"key":"1179_CR78","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1083\/jcb.200501131","volume":"170","author":"WM Bement","year":"2005","unstructured":"Bement WM, Benink HA, von Dassow G. A microtubule-dependent zone of active RhoA during cleavage plane specification. J Cell Biol. 2005;170:91\u2013101.","journal-title":"J Cell Biol"},{"key":"1179_CR79","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.devcel.2014.11.006","volume":"31","author":"B Mierzwa","year":"2014","unstructured":"Mierzwa B, Gerlich DW. Cytokinetic abscission: molecular mechanisms and temporal control. Dev Cell. 2014;31:525\u201338.","journal-title":"Dev Cell"},{"key":"1179_CR80","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-cellbio-101011-155718","volume":"28","author":"RA Green","year":"2012","unstructured":"Green RA, Paluch E, Oegema K. Cytokinesis in animal cells. Annu Rev Cell Dev Biol. 2012;28:29\u201358.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"1179_CR81","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41580-023-00682-z","volume":"25","author":"WM Bement","year":"2024","unstructured":"Bement WM, Goryachev AB, Miller AL, von Dassow G. Patterning of the cell cortex by Rho GTPases. Nat Rev Mol Cell Biol. 2024;25:290\u2013308.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1179_CR82","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1038\/sj.onc.1202792","volume":"18","author":"PM Ghosh","year":"1999","unstructured":"Ghosh PM, Ghosh-Choudhury N, Moyer ML, Mott GE, Thomas CA, Foster BA, Greenberg NM, Kreisberg JI. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Oncogene. 1999;18:4120\u201330.","journal-title":"Oncogene"},{"key":"1179_CR83","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.4103\/0366-6999.238145","volume":"131","author":"SY Chen","year":"2018","unstructured":"Chen SY, Du Y, Song J. MicroRNA-340 inhibits epithelial-mesenchymal transition by impairing rock-1-dependent Wnt\/beta-catenin signaling pathway in epithelial cells from human benign prostatic hyperplasia. Chin Med J. 2018;131:2008\u201312.","journal-title":"Chin Med J"},{"key":"1179_CR84","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.3390\/toxins5112241","volume":"5","author":"A Augspach","year":"2013","unstructured":"Augspach A, List JH, Wolf P, Bielek H, Schwan C, Elsasser-Beile U, Aktories K, Schmidt G. Activation of RhoA, B, C by yersinia cytotoxic necrotizing factor (CNFy) induces apoptosis in LNCaP prostate cancer cells. Toxins. 2013;5:2241\u201357.","journal-title":"Toxins"},{"key":"1179_CR85","first-page":"483","volume":"22","author":"QQ Gao","year":"2016","unstructured":"Gao QQ, Chen H, Chen Y, Xu ZP, Zhu LL, Yu W, Han YF, Dai YT. Effects of the Rho-kinase inhibitor fasudil on the invasion, migration, and apoptosis of human prostate cancer PC3 and DU145 cells. Zhonghua Nan Ke Xue. 2016;22:483\u201390.","journal-title":"Zhonghua Nan Ke Xue"},{"key":"1179_CR86","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1016\/j.yexcr.2008.07.012","volume":"314","author":"N Papadopoulou","year":"2008","unstructured":"Papadopoulou N, Charalampopoulos I, Alevizopoulos K, Gravanis A, Stournaras C. Rho\/ROCK\/actin signaling regulates membrane androgen receptor induced apoptosis in prostate cancer cells. Exp Cell Res. 2008;314:3162\u201374.","journal-title":"Exp Cell Res"},{"key":"1179_CR87","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/pros.20243","volume":"64","author":"J Bektic","year":"2005","unstructured":"Bektic J, Pfeil K, Berger AP, Ramoner R, Pelzer A, Schafer G, Kofler K, Bartsch G, Klocker H. Small G-protein RhoE is underexpressed in prostate cancer and induces cell cycle arrest and apoptosis. Prostate. 2005;64:332\u201340.","journal-title":"Prostate"},{"key":"1179_CR88","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/ddr.22010","volume":"84","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhu X, Xu C, Min F, Yu G, Chen C. Ulinastatin ameliorates the malignant progression of prostate cancer cells by blocking the RhoA\/ROCK\/NLRP3 pathway. Drug Dev Res. 2023;84:36\u201344.","journal-title":"Drug Dev Res"},{"key":"1179_CR89","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.3892\/mmr.2017.6545","volume":"15","author":"D Liu","year":"2017","unstructured":"Liu D, Mei X, Wang L, Yang X. RhoA inhibits apoptosis and increases proliferation of cultured SPCA1 lung cancer cells. Mol Med Rep. 2017;15:3963\u20138.","journal-title":"Mol Med Rep"},{"key":"1179_CR90","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/sj.onc.1210790","volume":"27","author":"S Zhu","year":"2008","unstructured":"Zhu S, Korzh V, Gong Z, Low BC. RhoA prevents apoptosis during zebrafish embryogenesis through activation of Mek\/Erk pathway. Oncogene. 2008;27:1580\u20139.","journal-title":"Oncogene"},{"key":"1179_CR91","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/ICU.0000000000000748","volume":"32","author":"ZA Syed","year":"2021","unstructured":"Syed ZA, Rapuano CJ. Rho kinase (ROCK) inhibitors in the management of corneal endothelial disease. Curr Opin Ophthalmol. 2021;32:268\u201374.","journal-title":"Curr Opin Ophthalmol"},{"key":"1179_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175648","volume":"946","author":"M Hanifa","year":"2023","unstructured":"Hanifa M, Singh M, Randhawa PK, Jaggi AS, Bali A. A focus on Rho\/ROCK signaling pathway: an emerging therapeutic target in depression. Eur J Pharmacol. 2023;946: 175648.","journal-title":"Eur J Pharmacol"},{"key":"1179_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173815","volume":"894","author":"M Iyer","year":"2021","unstructured":"Iyer M, Subramaniam MD, Venkatesan D, Cho SG, Ryding M, Meyer M, Vellingiri B. Role of RhoA-ROCK signaling in Parkinson\u2019s disease. Eur J Pharmacol. 2021;894: 173815.","journal-title":"Eur J Pharmacol"},{"key":"1179_CR94","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.stem.2010.06.018","volume":"7","author":"M Ohgushi","year":"2010","unstructured":"Ohgushi M, Matsumura M, Eiraku M, Murakami K, Aramaki T, Nishiyama A, Muguruma K, Nakano T, Suga H, Ueno M, Ishizaki T, Suemori H, Narumiya S, Niwa H, Sasai Y. Molecular pathway and cell state responsible for dissociation-induced apoptosis in human pluripotent stem cells. Cell Stem Cell. 2010;7:225\u201339.","journal-title":"Cell Stem Cell"},{"key":"1179_CR95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018271","volume":"6","author":"L Zhang","year":"2011","unstructured":"Zhang L, Valdez JM, Zhang B, Wei L, Chang J, Xin L. ROCK inhibitor Y-27632 suppresses dissociation-induced apoptosis of murine prostate stem\/progenitor cells and increases their cloning efficiency. PLoS ONE. 2011;6: e18271.","journal-title":"PLoS ONE"},{"key":"1179_CR96","doi-asserted-by":"publisher","first-page":"11641","DOI":"10.1074\/jbc.M411781200","volume":"280","author":"C Gajate","year":"2005","unstructured":"Gajate C, Mollinedo F. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J Biol Chem. 2005;280:11641\u20137.","journal-title":"J Biol Chem"},{"key":"1179_CR97","doi-asserted-by":"publisher","first-page":"29365","DOI":"10.1074\/jbc.M109.007971","volume":"284","author":"L Xiao","year":"2009","unstructured":"Xiao L, Eto M, Kazanietz MG. ROCK mediates phorbol ester-induced apoptosis in prostate cancer cells via p21Cip1 up-regulation and JNK. J Biol Chem. 2009;284:29365\u201375.","journal-title":"J Biol Chem"},{"key":"1179_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.599065","volume":"9","author":"J Xu","year":"2021","unstructured":"Xu J, Huang Y, Zhao J, Wu L, Qi Q, Liu Y, Li G, Li J, Liu H, Wu H. Cofilin: a promising protein implicated in cancer metastasis and apoptosis. Front Cell Dev Biol. 2021;9: 599065.","journal-title":"Front Cell Dev Biol"},{"key":"1179_CR99","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1111\/bph.14201","volume":"175","author":"Q Yu","year":"2018","unstructured":"Yu Q, Gratzke C, Wang Y, Herlemann A, Sterr CM, Rutz B, Ciotkowska A, Wang X, Strittmatter F, Stief CG, Hennenberg M. Inhibition of human prostate smooth muscle contraction by the LIM kinase inhibitors, SR7826 and LIMKi3. Br J Pharmacol. 2018;175:2077\u201396.","journal-title":"Br J Pharmacol"},{"key":"1179_CR100","first-page":"2630","volume":"62","author":"PM Ghosh","year":"2002","unstructured":"Ghosh PM, Bedolla R, Mikhailova M, Kreisberg JI. RhoA-dependent murine prostate cancer cell proliferation and apoptosis: role of protein kinase Czeta. Cancer Res. 2002;62:2630\u20136.","journal-title":"Cancer Res"},{"key":"1179_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.554078","volume":"12","author":"R Cannarella","year":"2021","unstructured":"Cannarella R, Condorelli RA, Barbagallo F, La Vignera S, Calogero AE. Endocrinology of the aging prostate: current concepts. Front Endocrinol. 2021;12: 554078.","journal-title":"Front Endocrinol"},{"key":"1179_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2023.127596","volume":"281","author":"J Li","year":"2024","unstructured":"Li J, Li Y, Zhou L, Li C, Liu J, Liu D, Fu Y, Wang Y, Tang J, Zhou L, Tan S, Wang L. The human microbiome and benign prostatic hyperplasia: current understandings and clinical implications. Microbiol Res. 2024;281: 127596.","journal-title":"Microbiol Res"},{"key":"1179_CR103","doi-asserted-by":"publisher","first-page":"8849","DOI":"10.3390\/ijms23168849","volume":"23","author":"S Radej","year":"2022","unstructured":"Radej S, Szewc M, Maciejewski R. Prostate infiltration by Treg and Th17 cells as an immune response to propionibacterium acnes infection in the course of benign prostatic hyperplasia and prostate cancer. Int J Mol Sci. 2022;23:8849.","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"1179_CR104","first-page":"5","volume":"76","author":"JD McConnell","year":"1995","unstructured":"McConnell JD. Prostatic growth: new insights into hormonal regulation. Br J Urol. 1995;76(Suppl 1):5\u201310.","journal-title":"Br J Urol"},{"key":"1179_CR105","first-page":"3463","volume":"84","author":"M Marcelli","year":"1999","unstructured":"Marcelli M, Cunningham GR. Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metab. 1999;84:3463\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"1179_CR106","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s11154-022-09730-z","volume":"23","author":"K Welen","year":"2022","unstructured":"Welen K, Damber JE. Androgens, aging, and prostate health. Rev Endocr Metab Disord. 2022;23:1221\u201331.","journal-title":"Rev Endocr Metab Disord"},{"key":"1179_CR107","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1007\/s00345-020-03090-6","volume":"38","author":"M Zhang","year":"2020","unstructured":"Zhang M, Luo C, Cui K, Xiong T, Chen Z. Chronic inflammation promotes proliferation in the prostatic stroma in rats with experimental autoimmune prostatitis: study for a novel method of inducing benign prostatic hyperplasia in a rat model. World J Urol. 2020;38:2933\u201343.","journal-title":"World J Urol"},{"key":"1179_CR108","first-page":"6820","volume":"20","author":"G Espinosa","year":"2013","unstructured":"Espinosa G, Esposito R, Kazzazi A, Djavan B. Vitamin D and benign prostatic hyperplasia\u2014a review. Can J Urol. 2013;20:6820\u20135.","journal-title":"Can J Urol"},{"key":"1179_CR109","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/pros.20463","volume":"67","author":"A Morelli","year":"2007","unstructured":"Morelli A, Vignozzi L, Filippi S, Vannelli GB, Ambrosini S, Mancina R, Crescioli C, Donati S, Fibbi B, Colli E, Adorini L, Maggi M. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA\/Rho kinase signaling in rat and human bladder. Prostate. 2007;67:234\u201347.","journal-title":"Prostate"},{"key":"1179_CR110","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1530\/JOE-11-0289","volume":"212","author":"L Vignozzi","year":"2012","unstructured":"Vignozzi L, Morelli A, Sarchielli E, Comeglio P, Filippi S, Cellai I, Maneschi E, Serni S, Gacci M, Carini M, Piccinni MP, Saad F, Adorini L, Vannelli GB, Maggi M. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol. 2012;212:71\u201384.","journal-title":"J Endocrinol"},{"key":"1179_CR111","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jsbmb.2012.02.007","volume":"132","author":"A Morelli","year":"2012","unstructured":"Morelli A, Comeglio P, Filippi S, Sarchielli E, Cellai I, Vignozzi L, Yehiely-Cohen R, Maneschi E, Gacci M, Carini M, Adorini L, Vannelli GB, Maggi M. Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. J Steroid Biochem Mol Biol. 2012;132:80\u201392.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1179_CR112","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/jsm.12478","volume":"11","author":"L Vignozzi","year":"2014","unstructured":"Vignozzi L, Filippi S, Comeglio P, Cellai I, Morelli A, Maneschi E, Sarchielli E, Gacci M, Carini M, Vannelli GB, Maggi M. Tadalafil effect on metabolic syndrome-associated bladder alterations: an experimental study in a rabbit model. J Sex Med. 2014;11:1159\u201372.","journal-title":"J Sex Med"},{"key":"1179_CR113","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1111\/j.1743-6109.2010.01811.x","volume":"7","author":"AK Chavalmane","year":"2010","unstructured":"Chavalmane AK, Comeglio P, Morelli A, Filippi S, Fibbi B, Vignozzi L, Sarchielli E, Marchetta M, Failli P, Sandner P, Saad F, Gacci M, Vannelli GB, Maggi M. Sex steroid receptors in male human bladder: expression and biological function. J Sex Med. 2010;7:2698\u2013713.","journal-title":"J Sex Med"},{"key":"1179_CR114","first-page":"4300","volume":"8","author":"H Zhang","year":"2016","unstructured":"Zhang H, Shi L, Ren GQ, Sun WW, Wang YB, Chen YK, Yin JN, Wan B. Dihydrotestosterone modulates endothelial progenitor cell function via RhoA\/ROCK pathway. Am J Transl Res. 2016;8:4300\u20139.","journal-title":"Am J Transl Res"},{"key":"1179_CR115","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.sxmr.2018.10.006","volume":"7","author":"G Rastrelli","year":"2019","unstructured":"Rastrelli G, Vignozzi L, Corona G, Maggi M. Testosterone and benign prostatic hyperplasia. Sex Med Rev. 2019;7:259\u201371.","journal-title":"Sex Med Rev"},{"key":"1179_CR116","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1006\/bbrc.2000.2343","volume":"269","author":"AV Somlyo","year":"2000","unstructured":"Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun. 2000;269:652\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"1179_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105093","volume":"160","author":"GR de Sousa","year":"2020","unstructured":"de Sousa GR, Vieira GM, Das CP, Pezuk JA, Brassesco MS. Should we keep rocking? Portraits from targeting Rho kinases in cancer. Pharmacol Res. 2020;160: 105093.","journal-title":"Pharmacol Res"},{"key":"1179_CR118","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/pros.20634","volume":"67","author":"CM Liu","year":"2007","unstructured":"Liu CM, Lo YC, Wu BN, Wu WJ, Chou YH, Huang CH, An LM, Chen IJ. cGMP-enhancing- and alpha1A\/alpha1D-adrenoceptor blockade-derived inhibition of Rho-kinase by KMUP-1 provides optimal prostate relaxation and epithelial cell anti-proliferation efficacy. Prostate. 2007;67:1397\u2013410.","journal-title":"Prostate"},{"key":"1179_CR119","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/hrt.2003.029470","volume":"91","author":"Y Fukumoto","year":"2005","unstructured":"Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, Abe K, Takeshita A, Shimokawa H. Acute vasodilator effects of a Rho-kinase inhibitor, Fasudil, in patients with severe pulmonary hypertension. Heart. 2005;91:391\u20132.","journal-title":"Heart"},{"key":"1179_CR120","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1177\/1074248418772814","volume":"23","author":"S Hanson","year":"2018","unstructured":"Hanson S, Terry MH, Moretta DT, Power GG, Wilson SM, Alam F, Ahsan F, Blood AB, Giri PC. Inhaled fasudil lacks pulmonary selectivity in thromboxane-induced acute pulmonary hypertension in newborn lambs. J Cardiovasc Pharmacol Ther. 2018;23:472\u201380.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"1179_CR121","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/archophthalmol.2007.76","volume":"126","author":"H Tanihara","year":"2008","unstructured":"Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, Araie M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol. 2008;126:309\u201315.","journal-title":"Arch Ophthalmol"},{"key":"1179_CR122","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1038\/s41433-024-03342-4","volume":"38","author":"JB Lin","year":"2024","unstructured":"Lin JB, Harris JM, Baldwin G, Goss D, Margeta MA. Ocular effects of Rho kinase (ROCK) inhibition: a systematic review. Eye. 2024;38:3418\u201328.","journal-title":"Eye"},{"key":"1179_CR123","doi-asserted-by":"publisher","first-page":"6037","DOI":"10.1038\/s41467-020-19932-1","volume":"11","author":"C Federico","year":"2020","unstructured":"Federico C, Alhallak K, Sun J, Duncan K, Azab F, Sudlow GP, de la Puente P, Muz B, Kapoor V, Zhang L, Yuan F, Markovic M, Kotsybar J, Wasden K, Guenthner N, Gurley S, King J, Kohnen D, Salama NN, Thotala D, Hallahan DE, Vij R, DiPersio JF, Achilefu S, Azab AK. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma. Nat Commun. 2020;11:6037.","journal-title":"Nat Commun"},{"key":"1179_CR124","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jconrel.2021.04.030","volume":"334","author":"TA Al-Hilal","year":"2021","unstructured":"Al-Hilal TA, Hossain MA, Alobaida A, Alam F, Keshavarz A, Nozik-Grayck E, Stenmark KR, German NA, Ahsan F. Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects. J Controlled Release. 2021;334:237\u201347.","journal-title":"J Controlled Release"},{"key":"1179_CR125","doi-asserted-by":"publisher","first-page":"7859","DOI":"10.18632\/aging.102294","volume":"11","author":"S Steurer","year":"2019","unstructured":"Steurer S, Hager B, Buscheck F, Hoflmayer D, Tsourlakis MC, Minner S, Clauditz TS, Hube-Magg C, Luebke AM, Simon R, Izbicki JR, Burandt E, Sauter G, Fraune C, Weidemann S, Schlomm T, Heinzer H, Haese A, Graefen M, Huland H, Heumann A. Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer. Aging. 2019;11:7859\u201379.","journal-title":"Aging"},{"key":"1179_CR126","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1002\/pros.23068","volume":"75","author":"B Xu","year":"2015","unstructured":"Xu B, Huang Y, Niu X, Tao T, Jiang L, Tong N, Chen S, Liu N, Zhu W, Chen M. Hsa-miR-146a-5p modulates androgen-independent prostate cancer cells apoptosis by targeting ROCK1. Prostate. 2015;75:1896\u2013903.","journal-title":"Prostate"},{"key":"1179_CR127","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ecoenv.2018.07.070","volume":"164","author":"C Zhang","year":"2018","unstructured":"Zhang C, Lu C, Wang Z, Feng G, Du E, Liu Y, Wang L, Qiao B, Xu Y, Zhang Z. Antimony enhances c-Myc stability in prostate cancer via activating CtBP2-ROCK1 signaling pathway. Ecotoxicol Environ Saf. 2018;164:61\u20138.","journal-title":"Ecotoxicol Environ Saf"},{"key":"1179_CR128","first-page":"3882","volume":"19","author":"H Liu","year":"2019","unstructured":"Liu H, Hou T, Ju W, Xing Y, Zhang X, Yang J. MicroRNA-122 downregulates Rho-associated protein kinase 2 expression and inhibits the proliferation of prostate carcinoma cells. Mol Med Rep. 2019;19:3882\u20138.","journal-title":"Mol Med Rep"},{"key":"1179_CR129","doi-asserted-by":"publisher","first-page":"16814","DOI":"10.1073\/pnas.1414189111","volume":"111","author":"A Zanin-Zhorov","year":"2014","unstructured":"Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, Chen W, Scher JU, Mo R, Depoil D, Rao N, Liu B, Wei J, Lucas S, Koslow M, Roche M, Schueller O, Weiss S, Poyurovsky MV, Tonra J, Hippen KL, Dustin ML, Blazar BR, Liu CJ, Waksal SD. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci USA. 2014;111:16814\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1179_CR130","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1200\/JCO.20.02754","volume":"39","author":"M Jagasia","year":"2021","unstructured":"Jagasia M, Lazaryan A, Bachier CR, Salhotra A, Weisdorf DJ, Zoghi B, Essell J, Green L, Schueller O, Patel J, Zanin-Zhorov A, Weiss JM, Yang Z, Eiznhamer D, Aggarwal SK, Blazar BR, Lee SJ. ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease. J Clin Oncol. 2021;39:1888\u201398.","journal-title":"J Clin Oncol"},{"key":"1179_CR131","volume":"70","author":"F Ali","year":"2022","unstructured":"Ali F, Ilyas A. Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease. Curr Res Transl Med. 2022;70: 103343.","journal-title":"Curr Res Transl Med"},{"key":"1179_CR132","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/blood-2015-10-678706","volume":"127","author":"R Flynn","year":"2016","unstructured":"Flynn R, Paz K, Du J, Reichenbach DK, Taylor PA, Panoskaltsis-Mortari A, Vulic A, Luznik L, MacDonald KK, Hill GR, Nyuydzefe MS, Weiss JM, Chen W, Trzeciak A, Serody JS, Aguilar EG, Murphy WJ, Maillard I, Munn D, Koreth J, Cutler CS, Antin JH, Ritz J, Waksal SD, Zanin-Zhorov A, Blazar BR. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016;127:2144\u201354.","journal-title":"Blood"},{"key":"1179_CR133","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s12975-019-00725-8","volume":"11","author":"L McKerracher","year":"2020","unstructured":"McKerracher L, Shenkar R, Abbinanti M, Cao Y, Peiper A, Liao JK, Lightle R, Moore T, Hobson N, Gallione C, Ruschel J, Koskimaki J, Girard R, Rosen K, Marchuk DA, Awad IA. A brain-targeted orally available ROCK2 inhibitor benefits mild and aggressive cavernous angioma disease. Transl Stroke Res. 2020;11:365\u201376.","journal-title":"Transl Stroke Res"},{"key":"1179_CR134","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1165\/rcmb.2023-0401OC","volume":"71","author":"S Hwang","year":"2024","unstructured":"Hwang S, Lee W, Ravi D, Devine W, Yong M, Diebold RB, Seung SA, Ng NW, Lee J, Gupta A, Koh JS. Novel Small-Molecule ROCK2 Inhibitor GNS-3595 attenuates pulmonary fibrosis in preclinical studies. Am J Respir Cell Mol Biol. 2024;71:430\u201341.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1179_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106539","volume":"137","author":"S Fu","year":"2023","unstructured":"Fu S, Wen Y, Peng B, Tang M, Shi M, Liu J, Yang Y, Si W, Guo Y, Li X, Yan T, Kang J, Pei H, Chen L. Discovery of indoline-based derivatives as effective ROCK2 inhibitors for the potential new treatment of idiopathic pulmonary fibrosis. Bioorg Chem. 2023;137: 106539.","journal-title":"Bioorg Chem"},{"key":"1179_CR136","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1039\/D4MD00438H","volume":"15","author":"R Cao","year":"2024","unstructured":"Cao R, Du F, Liu Z, Cai P, Qi M, Xiao W, Bao X, Chen G. The synthesis and bioactivities of ROCK2 inhibitors with 1,2-dithiolan-3-yl motif. RSC Med Chem. 2024;15:3576\u201396.","journal-title":"RSC Med Chem"},{"key":"1179_CR137","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s42003-023-05552-0","volume":"6","author":"A Zanin-Zhorov","year":"2023","unstructured":"Zanin-Zhorov A, Chen W, Moretti J, Nyuydzefe MS, Zhorov I, Munshi R, Ghosh M, Serdjebi C, MacDonald K, Blazar BR, Palmer M, Waksal SD. Selectivity matters: selective ROCK2 inhibitor ameliorates established liver fibrosis via targeting inflammation, fibrosis, and metabolism. Commun Biol. 2023;6:1176.","journal-title":"Commun Biol"},{"key":"1179_CR138","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1177\/0271678X241238845","volume":"44","author":"IA Mulder","year":"2024","unstructured":"Mulder IA, Abbinanti M, Woller SA, Ruschel J, Coutinho JM, de Vries HE, van Bavel E, Rosen K, McKerracher L, Ayata C. The novel ROCK2 selective inhibitor NRL-1049 preserves the blood-brain barrier after acute injury. J Cereb Blood Flow Metab. 2024;44:1238\u201352.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1179_CR139","doi-asserted-by":"publisher","first-page":"15205","DOI":"10.1021\/acs.jmedchem.3c01297","volume":"66","author":"Y Huang","year":"2023","unstructured":"Huang Y, Mao CR, Lou Y, Zhan S, Chen Z, Ding W, Ma Z. Design, synthesis, and biological evaluation of an orally bioavailable, potent, and selective rock2 inhibitor for psoriasis treatment. J Med Chem. 2023;66:15205\u201329.","journal-title":"J Med Chem"},{"key":"1179_CR140","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12964-024-01644-4","volume":"22","author":"Y Li","year":"2024","unstructured":"Li Y, Li J, Zhou L, Wang Z, Jin L, Cao J, Xie H, Wang L. Aberrant activation of TGF-beta\/ROCK1 enhances stemness during prostatic stromal hyperplasia. Cell Commun Signaling. 2024;22:257.","journal-title":"Cell Commun Signaling"},{"key":"1179_CR141","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41391-020-00277-1","volume":"24","author":"J Zhang","year":"2021","unstructured":"Zhang J, Zhang M, Tang J, Yin G, Long Z, He L, Zhou C, Luo L, Qi L, Wang L. Animal models of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2021;24:49\u201357.","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01179-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-025-01179-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01179-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T01:41:28Z","timestamp":1741311688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-025-01179-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":141,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["1179"],"URL":"https:\/\/doi.org\/10.1007\/s13577-025-01179-x","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}}],"article-number":"48"}}